The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)

Behavioral and Brain Functions

Volumn 2, Issue , 2006, Pages

  Sagvolden, Terje ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; GUANFACINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HYPERACTIVITY; IMPULSIVENESS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VISUAL DISCRIMINATION;

EID: 33846673339     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-2-41     Document Type: Article

References (25)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-IV Washington, D.C., Author 4 1994 78-85
2. Sagvolden T Archer T Future perspectives on ADD research - An irresistible challenge Attention deficit disorder: Clinical and basic research Hillsdale, N.J., Lawrence Erlbaum Associates Sagvolden T and Archer T 1989 369-389
3. Johansen EB Aase H Meyer A Sagvolden T Attention-deficit/hyperactivity disorder (ADHD) behaviour explained by dysfunctioning reinforcement and extinction processes Behav Brain Res 2002 130 37-45 10.1016/ S0166-4328(01)00434-X 11864716
4. Sagvolden T Johansen EB Aase H Russell VA A dynamic developmental theory of Attention-Deficit/Hyperactivity Disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes Behav Brain Sci 2005 28 397-419 10.1017/S0140525X05000075 16209748
5. Johansen EB Sagvolden T Aase H Russell VA The dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD): Present status and future perspectives Behav Brain Sci 2005 28 451-454 10.1017/ S0140525X05430071
6. Barkley RA Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD Psychol Bull 1997 121 65-94 10.1037/0033-2909.121.1.65 9000892
7. Tannock R Attention deficit hyperactivity disorder: Advances in cognitive, neurobiological, and genetic research J Child Psychol Psychiatry 1998 39 65-99 10.1017/S0021963097001777 9534087
8. Arnsten AF Dudley AG Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder Behav Brain Funct 2005 1 2 1143775 15916700 10.1186/1744-9081-1-2
9. Russell VA Sagvolden T Johansen EB Animal models of attention-deficit hyperactivity disorder Behav Brain Funct 2005 1 9 1180819 16022733 10.1186/1744-9081-1-9
10. Goldman-Rakic PS Cellular basis of working memory Neuron 1995 14 477-485 10.1016/0896-6273(95)90304-6 7695894
11. Tannock R Hypodopaminergic function influences learning and memory as well as delay gradients Behav Brain Sci 2005 28 444-445 10.1017/ S0140525X05400072
12. Biederman J Spencer T Wilens T Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder Int J Neuropharmacol 2004 7 77-97
13. Banaschewski T Roessner V Dittmann RW Santosh PJ Rothenberger A Non-stimulant medications in the treatment of ADHD Eur Child Adolesc Psychiatry 2004 13 102-116 10.1007/s00787-004-1010-x
14. Arnsten AFT Li BM Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions Biol Psychiatry 2005 57 1377-1384 10.1016/j.biopsych.2004.08.019 15950011
15. Avery RA Franowicz JS Studholme C van Dyck CH Arnsten AF The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task Neuropsychopharmacology 2000 23 240-249 10.1016/S0893-133X(00)00111-1 10942848
16. Sagvolden T The spontaneously hypertensive rat as a model of ADHD Stimulant drugs and ADHD: Basic and clinical neuroscience New York, Oxford University Press Solanto MV, Arnsten AFT and Castellanos FX 2001 221-237
17. Sagvolden T Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/ HD) Neurosci Biobehav Rev 2000 24 31-39 10.1016/S0149-7634(99)00058-5 10654658
18. Sagvolden T Russell VA Aase H Johansen EB Farshbaf M Rodent models of attention-deficit/hyperactivity disorder Biol Psychiatry 2005 57 1239-1247 10.1016/j.biopsych.2005.02.002 15949994
19. Russell V Allie S Wiggins T Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat Behav Brain Res 2000 117 69-74 10.1016/S0166-4328(00)00291-6 11099759
20. Tsuda K Tsuda S Masuyama Y Goldstein M Norepinephrine release and neuropeptide Y in medulla oblongata of spontaneously hypertensive rats Hypertension 1990 15 784-790 1972138
21. Catania AC Learning N.J., Englewoods Cliffs, Prentice Hall 4 1998
22. StatSoft STATISTICA for Windows Tulsa, OK, StatSoft, Inc. 1999 Release 5.5
23. Steere JC Arnsten AF The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys Behav Neurosci 1997 111 883-891 10.1037/ 0735-7044.111.5.883 9383511
24. Franowicz JS Arnsten AF The alpha-2a noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys Psychopharmacology (Berl) 1998 136 8-14 10.1007/s002130050533 9537677
25. Arnsten AF Steere JC Hunt RD The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention- deficit hyperactivity disorder Arch Gen Psychiatry 1996 53 448-455 8624188